Format

Send to

Choose Destination
Clin Endocrinol (Oxf). 2014 Jun;80(6):773-81. doi: 10.1111/cen.12446. Epub 2014 Mar 24.

Insulin-like growth factor-II: its role in metabolic and endocrine disease.

Author information

1
Peptide Hormones Supraregional Assay Service (SAS), Department of Clinical Biochemistry, Royal Surrey County Hospital NHS Trust, Guildford, UK; Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Abstract

Insulin-like growth factor-II (IGF-II) is a widely expressed 7·5 kDa mitogenic peptide hormone. Although it is abundant in serum, understanding of its physiological role is limited compared with that of IGF-I. IGF-II regulates foetal development and differentiation, but its role in adults is less well understood. Evidence suggests roles in a number of tissues including skeletal muscle, adipose tissue, bone and ovary. Altered IGF-II expression has been observed in metabolic conditions, notably obesity, diabetes and the polycystic ovary syndrome. This article summarizes what is known about the actions of IGF-II and its dysregulation in metabolic and endocrine diseases. The possible causes and consequences of dysregulation are discussed along with the implications for diagnostic tests and future research.

PMID:
24593700
DOI:
10.1111/cen.12446
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center